{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T04:06:09Z","timestamp":1785038769727,"version":"3.55.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007366","name":"Fondazione Italiana Sclerosi Multipla","doi-asserted-by":"publisher","award":["2011\/R\/13"],"award-info":[{"award-number":["2011\/R\/13"]}],"id":[{"id":"10.13039\/100007366","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007366","name":"Fondazione Italiana Sclerosi Multipla","doi-asserted-by":"publisher","award":["2015\/R\/09"],"award-info":[{"award-number":["2015\/R\/09"]}],"id":[{"id":"10.13039\/100007366","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.lfs.2025.123938","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T07:02:57Z","timestamp":1756191777000},"page":"123938","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Substituted 2-pyrrolinone compounds as inhibitors of B-cell activating factor (BAFF) for autoimmune diseases treatment"],"prefix":"10.1016","volume":"380","author":[{"given":"Stefania","family":"Olla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Laura","family":"Idda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manila","family":"Deiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Lodde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Delogu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Cristian","family":"Caria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Floris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cucca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2025.123938_bb0005","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nrd4309","article-title":"Lessons learned from the fate of AstraZeneca\u2019s drug pipeline: a five-dimensional framework","volume":"13","author":"Cook","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.lfs.2025.123938_bb0010","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/ng.3314","article-title":"The support of human genetic evidence for approved drug indications","volume":"47","author":"Nelson","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.lfs.2025.123938_bb0015","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrd4051","article-title":"Validating therapeutic targets through human genetics","volume":"12","author":"Plenge","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.lfs.2025.123938_bb0020","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf2608","article-title":"Disciplined approach to drug discovery and early development","volume":"8","author":"Plenge","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.lfs.2025.123938_bb0025","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.tig.2018.04.004","article-title":"Genetic-Driven Druggable Target Identification and Validation","volume":"34","author":"Floris","year":"2018","journal-title":"Trends Genet."},{"key":"10.1016\/j.lfs.2025.123938_bb0030","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41573-022-00561-w","article-title":"Using human genetics to improve safety assessment of therapeutics","volume":"22","author":"Carss","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.lfs.2025.123938_bb0035","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1056\/NEJMoa1610528","article-title":"Overexpression of the Cytokine BAFF and Autoimmunity Risk","volume":"376","author":"Steri","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lfs.2025.123938_bb0040","doi-asserted-by":"crossref","first-page":"12040","DOI":"10.1093\/nar\/gky866","article-title":"Cooperative translational control of polymorphic BAFF by NF90 and miR-15a","volume":"46","author":"Idda","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.lfs.2025.123938_bb0045","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.coi.2007.04.008","article-title":"B cells and the BAFF\/APRIL axis: fast-forward on autoimmunity and signaling","volume":"19","author":"Mackay","year":"2007","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.lfs.2025.123938_bb0050","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/1521-4141(200207)32:7<2004::AID-IMMU2004>3.0.CO;2-5","article-title":"BAFF is a survival and maturation factor for mouse B cells","volume":"32","author":"Rolink","year":"2002","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.lfs.2025.123938_bb0055","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1084\/jem.192.1.129","article-title":"BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population","volume":"192","author":"Thompson","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.lfs.2025.123938_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00835","article-title":"Targeting B cells and plasma cells in autoimmune diseases","volume":"9","author":"Hofmann","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2025.123938_bb0065","article-title":"Mechanisms of Action for Small Molecules Revealed by Structural Biology in Drug Discovery","volume":"21","author":"Li","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2025.123938_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22168370","article-title":"Reviewing the Significance of Blood-Brain Barrier Disruption in Multiple Sclerosis Pathology and Treatment","volume":"22","author":"Balasa","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2025.123938_bb0075","author":"Asinex"},{"key":"10.1016\/j.lfs.2025.123938_bb0080","author":"Sigma"},{"key":"10.1016\/j.lfs.2025.123938_bb0090","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1006\/jmbi.2001.5296","article-title":"Crystal structure of extracellular human BAFF, a TNF family member that stimulates B lymphocytes","volume":"315","author":"Karpusas","year":"2002","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.lfs.2025.123938_bb0095","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nature01543","article-title":"Ligand-receptor binding revealed by the TNF family member TALL-1","volume":"423","author":"Liu","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2025.123938_bb0100","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/jcc.20289","article-title":"Scalable molecular dynamics with NAMD","volume":"26","author":"Phillips","year":"2005","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.lfs.2025.123938_bb0105","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1021\/ct9000685","article-title":"ACEMD: Accelerating Biomolecular Dynamics in the Microsecond Time Scale","volume":"5","author":"Harvey","year":"2009","journal-title":"J. Chem. Theory Comput."},{"key":"10.1016\/j.lfs.2025.123938_bb0110","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/jcc.20011","article-title":"SPICKER: a clustering approach to identify near-native protein folds","volume":"25","author":"Zhang","year":"2004","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.lfs.2025.123938_bb0115","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.lfs.2025.123938_bb0120","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1002\/prot.23106","article-title":"The VSGB 2.0 model: a next generation energy model for high resolution protein structure modeling","volume":"79","author":"Li","year":"2011","journal-title":"Proteins"},{"key":"10.1016\/j.lfs.2025.123938_bb0125","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1021\/acs.jctc.1c00302","article-title":"OPLS4: Improving Force Field Accuracy on Challenging Regimes of Chemical Space","volume":"17","author":"Lu","year":"2021","journal-title":"J Chem Theory Comput"},{"key":"10.1016\/j.lfs.2025.123938_bb0130","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1387-2656(05)11004-7","article-title":"Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction","volume":"11","author":"Berridge","year":"2005","journal-title":"Biotechnol. Annu. Rev."},{"key":"10.1016\/j.lfs.2025.123938_bb0135","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/sj.bjp.0707373","article-title":"Origin and evolution of high throughput screening","volume":"152","author":"Pereira","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.lfs.2025.123938_bb0140","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/nrd3368","article-title":"Impact of high-throughput screening in biomedical research","volume":"10","author":"Macarron","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.lfs.2025.123938_bb0145","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3390\/cells3010079","article-title":"Development of a Novel BAFF Responsive Cell Line Suitable for Detecting Bioactive BAFF and Neutralizing Antibodies against BAFF-Pathway Inhibiting Therapeutics","volume":"3","author":"Hu","year":"2014","journal-title":"Cells"},{"key":"10.1016\/j.lfs.2025.123938_bb0150","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/cea.13347","article-title":"Incidental pharmacogenetics findings in an HLA-related research: Considerations for primary prevention","volume":"49","author":"Bakhtiar","year":"2019","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.lfs.2025.123938_bb0155","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd3078","article-title":"How to improve R&D productivity: the pharmaceutical industry\u2019s grand challenge","volume":"9","author":"Paul","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.lfs.2025.123938_bb0160","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/ene.14105","article-title":"Failed B cell survival factor trials support the importance of memory B cells in multiple sclerosis","volume":"27","author":"Baker","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.lfs.2025.123938_bb0165","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cytogfr.2021.11.004","article-title":"B cell-activating factor and its targeted therapy in autoimmune diseases","volume":"64","author":"Zhang","year":"2022","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.lfs.2025.123938_bb0170","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ceb.2017.10.002","article-title":"Signalling for B cell survival","volume":"51","author":"Schweighoffer","year":"2018","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.lfs.2025.123938_bb0175","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1084\/jem.190.11.1697","article-title":"Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations","volume":"190","author":"Mackay","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.lfs.2025.123938_bb0180","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1002\/art.11354","article-title":"B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations","volume":"48","author":"Stohl","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.lfs.2025.123938_bb0185","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2025.123938_bb0190","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1001\/archneurol.2010.99","article-title":"Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis","volume":"67","author":"Piccio","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.lfs.2025.123938_bb0195","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","article-title":"B cell depletion therapies in autoimmune disease: advances and mechanistic insights","volume":"20","author":"Lee","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.lfs.2025.123938_bb0200","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.kint.2019.12.025","article-title":"Anti-CD20-mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives","volume":"97","author":"Crickx","year":"2020","journal-title":"Kidney Int."},{"key":"10.1016\/j.lfs.2025.123938_bb0205","doi-asserted-by":"crossref","first-page":"550","DOI":"10.4103\/0019-5154.190107","article-title":"Belimumab in Systemic Lupus Erythematosus","volume":"61","author":"Srivastava","year":"2016","journal-title":"Indian J. Dermatol."},{"key":"10.1016\/j.lfs.2025.123938_bb0210","article-title":"The Role of Belimumab in Systemic Lupus Erythematosis: A Systematic Review","volume":"14","author":"Joy","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.lfs.2025.123938_bb0215","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70055","article-title":"A first-in-human, randomized study of the safety, pharmacokinetics and pharmacodynamics of povetacicept, an enhanced dual BAFF\/APRIL antagonist, in healthy adults","volume":"17","author":"Davies","year":"2024","journal-title":"Clin. Transl. Sci."},{"issue":"Suppl. 9","key":"10.1016\/j.lfs.2025.123938_bb0220","article-title":"AUR200: An Improved BAFF\/APRIL Inhibitor with Increased Potency and Safety for the Treatment of B Cell-Mediated Diseases","volume":"74","author":"Morales","year":"2022","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.lfs.2025.123938_bb0225","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1177\/0271678X20985946","article-title":"Understanding the brain uptake and permeability of small molecules through the BBB: A technical overview","volume":"41","author":"Chowdhury","year":"2021","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.lfs.2025.123938_bb0230","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1359-6446(03)02828-9","article-title":"ADME-Tox in drug discovery: integration of experimental and computational technologies","volume":"8","author":"Yu","year":"2003","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.lfs.2025.123938_bb0235","doi-asserted-by":"crossref","first-page":"6155","DOI":"10.1016\/j.bmcl.2007.09.061","article-title":"Substituted 2-pyrrolinone inhibitors of HIV-1 integrase","volume":"17","author":"Dayam","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.lfs.2025.123938_bb0240","article-title":"The role of B cell-activating factor system in autoimmune diseases: mechanisms, disease implications, and therapeutic advances","volume":"16","author":"Li","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2025.123938_bb0245","doi-asserted-by":"crossref","first-page":"7253","DOI":"10.1021\/acs.jmedchem.2c01824","article-title":"Explaining Blood-Brain Barrier Permeability of Small Molecules by Integrated Analysis of Different Transport Mechanisms","volume":"66","author":"Cornelissen","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.lfs.2025.123938_bb0250","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252313121","article-title":"Overcoming Challenges in Small-Molecule Drug Bioavailability: A Review of Key Factors and Approaches","volume":"25","author":"Wu","year":"2024","journal-title":"Int. J. Mol. Sci."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320525005739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320525005739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T02:29:29Z","timestamp":1777429769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320525005739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":49,"alternative-id":["S0024320525005739"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2025.123938","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Substituted 2-pyrrolinone compounds as inhibitors of B-cell activating factor (BAFF) for autoimmune diseases treatment","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2025.123938","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"123938"}}